Neuroscience

#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

How technology and science are driving neuroscience

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience Parkinson's disease
#Biology #Drug discovery #Neuroscience #Parkinson's

Parkinson’s disease and CDNF: Turning a neurotrophic factor into a viable therapy 

Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease.   Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. If a… Read More

#Exclusive Content

#Ajna Biosciences #Autism #Neuroscience

The promise of a botanical approach to autism

DDW Editor Reece Armstrong speaks to Joel Stanley, CEO of Ajna BioSciences, about the challenges of developing therapies for autism and why a multi-compound approach may be key to treating symptoms.  RA: What are the challenges of discovering and developing effective therapies for autism?   JS: Autism is an incredibly broad spectrum, which makes it fundamentally different from… Read More

#Exclusive Content

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Webinar: Opportunities in neuroscience drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Demyelination of neuron
#MND #Neurodegenerative disorders #Neuroscience #University of Queensland

New drug could be a ‘breakthrough’ for MND

University of Queensland researchers have developed a drug that activates a hard-to-target immune receptor — a breakthrough that researchers say could lead to new treatments for neurodegenerative conditions like Motor Neurone Disease (MND). In an international collaboration with the Indian Institute of Technology, The University of Tokyo and… Read More

#Editor's Choice #News

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

DDW Neuroscience webinar: Opportunities for drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of new therapies… Read More

Webinar date:
Sponsored by BioIVT
#Webinars

#AI #Autism #Drug design #Drug discovery #Immunotherapy #Neuroscience

Read the Summer issue of DDW

The latest issue of Drug Discovery World is out now. The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and Investors – investment challenges and opportunities for drug developers. It also included features on: The importance of tech and collaboration for immunotherapies The… Read More

#News

Neuroscience Parkinson's disease
#Autobahn Therapeutics #Bipolar #Neuroscience #Phase II trial #Psychiatry

Bipolar treatment leads to rapid antidepressant effects

A treatment for patients with bipolar I or bipolar II depression has demonstrated durable antidepressant effects, results show. Elunetirom, developed by Autobahn Therapeutics, is a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist. In the Phase II AMPLIFY-BD trial, elunetirom was evaluated as an adjunctive… Read More

#News

Drugs targeting amyloid Plaque
#Alzheimer's #Monoclonal antibodies #Neurodegenerative disorders #Neuroscience

Refining, not abandoning, the amyloid hypothesis: Precision medicine after the Cochrane review 

Susan Abushakra, MD, Chief Medical Officer at Alzheon, discusses the validity of the amyloid hypothesis in light of the recent Cochrane review that found no clinical benefit of anti-amyloid monoclonal antibodies.  A Cochrane systematic review published in April 2026 by Nonino, et al. – examining 17 randomised controlled trials encompassing… Read More

#Exclusive Content

#Equity finance #Investment #Neuroscience

MindMaze Therapeutics raises CHF 8m in equity financing 

Neurotherapeutics company MindMaze Therapeutics has announced it has raised CHF 8 million (€8.7 million) in strategic equity financing.  The financing has been raised through a definitive agreement with Neuro.io, which will acquire a strategic equity position in the company.  MindMaze Therapeutics says it will use the funds raised to support… Read More

#News

TARGA imager
#App note #Imaging #Neurodevelopmental disorders #Neuroscience

App Note: Neurodevelopmental disease revealed with TARGA Imager

The study of neurodevelopmental diseases such as schizophrenia requires imaging tools capable of capturing complex neuronal behaviour at scale. This Application Note identifies Lumencor’s TARGA Imager enabling high-speed calcium imaging using NGN2 neurons and stem cell–derived neuronal models to study collective cellular dynamics with exceptional spatial and temporal resolution. Read More

#News

#Neuroinflammation #Neuroscience #University of Cambridge

Collaboration set to develop neuroinflammation therapeutics 

Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation.  The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed… Read More

#News

MRI of the brain
#Cell therapy #epilepsy #Mergers and acquisitions #Neurona Therapeutics #Neuroscience #UCB

UCB to acquire epilepsy specialists Neurona Therapeutics

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio.   Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.  UCB will pay $650 million upfront and up… Read More

#Business & Investment #News

Brain Awareness Week
#Depression #Drug discovery #Neuroscience #Psychedelics

Designing scalable psychedelic therapies for treatment‑resistant depression 

Kevin Craig, Chief Medical Officer of AtaiBeckley, discusses the current therapeutic landscape for major depressive disorder and therapeutic advances for this hard-to-treat disease.   Major depressive disorder (MDD), or depression, remains one of the most urgent and complex challenges in mental health. More than 300 million people1 worldwide live with the condition, but a substantial proportion of these people – commonly estimated at 30-502– do… Read More

#Exclusive Content

#Neurodegenerative disorders #Neuroscience #Oncology

This week in Drug Discovery (30 March – 3 April) 

News round-up for 30 March – 3 April by Diana Turner, Deputy Editor, DDW. This week, there have been a number of developments in neuroscience drug discovery. Elsewhere, a new treatment for platinum-resistant epithelial ovarian cancer has been approved in the US. The top stories: … Read More

#News